98. Eosinophilic gastrointestinal disease Clinical trials / Disease details

Clinical trials : 171 / Drugs : 184 - (DrugBank : 47) / Drug target genes : 42 - Drug target pathways : 141

diseases per page:

Showing 1 to 10 of 171 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2021210067	07/03/2022	02/02/2022	A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLEBLIND,PLACEBO-CONTROLLED INDUCTION AND MAINTENANCE STUDY T ...	A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLEBLIND,PLACEBO-CONTROLLED INDUCTION AND MAINTENANCE STUDY T ...	Eosinophilic gastroenteritis	CC-93538 is administered subcutaneously at a dose of 360 mg weekly in adults and adolescents of 12 y ...	Zhang Changliang	NULL	Pending	>= 12age old	<= 75age old	Both	45	Phase 3	Japan
2	NCT05246085 (ClinicalTrials.gov)	March 1, 2022	1/2/2022	Evaluating Adrenal Insufficiency in Adults With Eosinophilic Esophagitison Chronic Swallowed Topical ...	Evaluating Adrenal Insufficiency in Adults With Eosinophilic Esophagitison Chronic Swallowed Topical ...	Eosinophilic Esophagitis	Diagnostic Test: Cortisol level	University of Colorado, Denver	NULL	Not yet recruiting	18 Years	85 Years	All	300		NULL
3	NCT05247866 (ClinicalTrials.gov)	March 2022	21/12/2021	Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis	Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis	Eosinophilic Esophagitis	Dietary Supplement: EoE food introduction-1st;Dietary Supplement: E0E food introduction-2nd;Dietary ...	Children's Hospital of Philadelphia	Regeneron Pharmaceuticals;Genzyme, a Sanofi Company	Not yet recruiting	6 Years	25 Years	All	30	Phase 4	United States
4	EUCTR2020-004335-24-PT (EUCTR)	24/02/2022	03/12/2021	A study to evaluate the long-term safety of CC-93538 in adult and adolescent patients who have eosin ...	A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY O ...	EOSINOPHILIC ESOPHAGITIS MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinoph ...	Product Name: Cendakimab Product Code: CC -93538 INN or Proposed INN: Cendakimab	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	259	Phase 3	United States;Portugal;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;Canada;Argentina;Belgiu ...
5	JPRN-jRCT2031210574	10/02/2022	22/01/2022	A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY O ...	A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY O ...	eosinophilic esophagitis	All subjects will be administered CC-93538 at a dose of 360 mg SC once weekly.	Zhang Changliang	NULL	Pending	>= 12age old	<= 75age old	Both	22	Phase 3	United States of America;Canada;United Kingdom;Italy;Israel;Portugal;Germany;Switzerland;Poland;Spai ...
6	EUCTR2020-004335-24-IT (EUCTR)	08/02/2022	29/10/2021	A study to evaluate the long-term safety of CC-93538 in adult and adolescent patients who have eosin ...	A Phase 3, Multicenter, Multinational, Open-Label Extension Study to evaluate the Long-Term Safety o ...	EOSINOPHILIC ESOPHAGITIS MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinoph ...	Trade Name: Cendakimab Product Name: Cendakimab Product Code: [CC -93538] INN or Proposed INN: Cendakima ...	CELGENE INTERNATIONAL II SàRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	259	Phase 3	United States;Portugal;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;Canada;Argentina;Belgiu ...
7	NCT04835168 (ClinicalTrials.gov)	January 30, 2022	10/3/2021	Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis	A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Safety and Pharmacokin ...	Eosinophilic Esophagitis	Drug: BT -11 500mg;Drug: BT -11 1000mg;Drug: BT-11 Placebo	Landos Biopharma Inc.	NULL	Not yet recruiting	18 Years	65 Years	All	36	Phase 1	NULL
8	NCT05251909 (ClinicalTrials.gov)	January 18, 2022	6/8/2021	Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis ( ...	A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to ...	Eosinophilic Gastritis;Eosinophilic Gastroenteritis	Biological: Benralizumab;Biological: Placebo	AstraZeneca	NULL	Recruiting	12 Years	130 Years	All	230	Phase 3	United States;Australia;Brazil;Canada;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Ukraine;Vi ...
9	EUCTR2020-004335-24-DE (EUCTR)	14/01/2022	30/07/2021	A study to evaluate the long-term safety of CC-93538 in adult and adolescent patients who have eosin ...	A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY O ...	EOSINOPHILIC ESOPHAGITIS MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinoph ...	Product Name: Cendakimab Product Code: CC -93538 INN or Proposed INN: Cendakimab	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	259	Phase 3	United States;Portugal;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;Canada;Argentina;Belgiu ...
10	JPRN-jRCT2031210500	14/01/2022	18/12/2021	Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/or Gastroenteritis ( ...	A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to ...	Eosinophilic gastritis, Eosinophilic gastroenteritis	The patients are planned to be randomly assigned to receive either a fixed SC dose of Benralizumabor ...	Hibi Kazushige	NULL	Recruiting	>= 12age old	<= 130age old	Both	230	Phase 3	Australia;China;Vietnam;Italy;France;Poland;Spain;Brazil;Canada;America;Netherlands;Ukraine;Israel;J ...

First Previous1 2 3 4 5…18Next Last